Biogen Dirección

Dirección controles de criterios 2/4

Biogen's El consejero delegado es Chris Viehbacher , nombrado en Nov 2022, tiene un mandato de 1.08 años. la remuneración anual total es $30.49M , compuesta por 0.5% salario y 99.5% primas, incluidas acciones y opciones de la empresa. posee directamente 0.005% de las acciones de la empresa, por valor de CHF1.51M . La antigüedad media del equipo directivo y del consejo de administración es de 3.9 años y 4.5 años respectivamente.

Información clave

Chris Viehbacher

Chief Executive Officer (CEO)

US$30.5m

Compensación total

Porcentaje del salario del CEO	0.5%
Permanencia del CEO	1.4yrs
Participación del CEO	0.005%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Viehbacher en comparación con los beneficios de Biogen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

Compensación vs. Mercado: Chris($USD30.49M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD6.69M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Chris con los resultados de la empresa.

CEO

Chris Viehbacher (62 yo)

1.4yrs

Permanencia

US$30,488,593

Compensación

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Viehbacher	President	1.4yrs	US$30.49m	0.0048% $ 1.2m
Michael McDonnell	Executive VP & CFO	3.7yrs	US$7.21m	0.013% $ 3.4m
Nicole Murphy	Head of Pharmaceutical Operations & Technology	2.3yrs	US$4.93m	0.0066% $ 1.7m
Susan Alexander	Executive VP & Chief Legal Officer	18.3yrs	US$6.79m	0.036% $ 9.1m
Ginger Gregory	Executive VP & Chief Human Resources Officer	6.8yrs	US$5.08m	0.0094% $ 2.4m
Robin Kramer	Senior VP & Chief Accounting Officer	5.4yrs	sin datos	0.0043% $ 1.1m
Charles Triano	Senior VP & Head of Investor Relations	1.1yrs	sin datos	sin datos
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	4.3yrs	sin datos	sin datos
Adam Keeney	Executive VP & Head of Corporate Development	less than a year	sin datos	sin datos
Alisha Alaimo	President & Head of North America	6.8yrs	sin datos	sin datos
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	6.8yrs	sin datos	sin datos
Priya Singhal	Executive VP	4.3yrs	sin datos	0.0034% $ 864.7k

4.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: BIIBEl equipo directivo de la empresa se considera experimentado (3.9 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christopher Viehbacher	President	1.4yrs	US$30.49m	0.0048% $ 1.2m
Stephen Sherwin	Independent Director	14.1yrs	US$435.25k	0.012% $ 3.1m
William Hawkins	Independent Director	4.8yrs	US$410.25k	0.0029% $ 741.2k
Caroline Dorsa	Independent Chair of the Board	14.3yrs	US$425.25k	0.016% $ 4.1m
Eric Rowinsky	Independent Director	14.1yrs	US$410.25k	0.014% $ 3.5m
Maria Freire	Independent Director	2.8yrs	US$413.79k	0.0015% $ 380.9k
Monish Patolawala	Director	less than a year	sin datos	sin datos
Jesus Mantas	Independent Director	4.8yrs	US$417.75k	0.0035% $ 900.7k
Susan Langer	Director	less than a year	sin datos	0.00032% $ 82.4k

4.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de BIIB se considera experimentada (4.5 años de antigüedad promedio).

Biogen Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Recent updates

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: EPS: US$4.09 (vs US$7.25 in 2Q 2022)

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Insider recently sold CHF716k worth of stock

First quarter 2023 earnings released: EPS: US$2.69 (vs US$2.07 in 1Q 2022)

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$20.97 (vs US$10.44 in FY 2021)

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Co., Ltd. and Biogen Inc. Announce European Medicines Agency Accepts Marketing Authorization Application for Lecanemab

Biogen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Biogen Names Priya Singhal as Executive Vice President, Head of Development

U.S. Food and Drug Administration Accepts Biogen Inc.'s Biologics License Application for BIIB800

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Biogen Inc. Announces European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of Als

Biogen Inc. Announces Executive Changes

Biogen Inc. Revises Revenue Guidance for the Full Year 2022

Third quarter 2022 earnings released: EPS: US$7.86 (vs US$2.22 in 3Q 2021)

Biogen Inc. Announces FDA's 3-Month Extension of Review Period for the New Drug Application for Tofersen

Biogen Inc. to Report Q3, 2022 Results on Oct 25, 2022

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Boston Properties, Inc. (NYSE:BXP) acquired 125 Broadway, A six story 271,000 Square Foot Laboratory/Life Sciences Property from Biogen Inc. (NasdaqGS:BIIB) for $592 million.

Biogen Inc. Announces That the New England Journal of Medicine Has Published A Second Manuscript Detailing Positive Results from the Company’s Two-Part Phase 2 Lilac Study, Which Evaluated Litifilimab, an Investigational Drug, in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

Second quarter 2022 earnings released: EPS: US$7.25 (vs US$3.00 in 2Q 2021)

Biogen Inc. Updates Earnings Guidance for Full Year 2022

Biogen Inc. to Report Q2, 2022 Results on Jul 20, 2022

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization Accepts A New Role Outside of Biogen, Inc, Effective June 30, 2022

Biogen Inc. Presents New Data from Clinical Studies Aimed at Assessing Remaining Unmet Needs for People Living with Spinal Muscular Atrophy and Evaluating the Potential Impact of SPINRAZA

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor in Parkinson's Disease

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo